Respiratory Exacerbations Increase with Chronic $PM_{2.5}$ Exposure in Current and Former Smokers

James L. Crooks PhD MS[1,2,*], Zhongying Wang MS[3], Morteza Karimzadeh PhD[3], David A. Lynch MB BCh[4], Surya P. Bhatt MD [5], Craig P. Hersh MD, MPH[6] , Dawn L. DeMeo MD, MPH[6], David Baraghoshi PhD[1], Min Hyung Ryu PhD[7], Elizabeth A. Regan MD, PhD[8]

1. Division of Biostatistics and Bioinformatics, National Jewish Health
2. Department of Epidemiology, Colorado School of Public Health
3. Department of Geography, Institute of Behavioral Science University of Colorado Boulder
4. Department of Radiology, National Jewish Health
5. Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama Birmingham
6. Channing Division of Network Medicine, Harvard Medical School
7. Faculty of Medicine, Division of Respiratory Medicine, University of British Columbia
8. Division of Rheumatology, Department of Medicine, National Jewish Health

Corresponding Author:
James L. Crooks PhD
Division of Biostatistics and Bioinformatics,
National Jewish Health
1400 Jackson St.
Denver, CO 80206
Email: Crooksj@njhealth.org

Word Count – XXX of 3500

Author Contributions:
JLC – conception, study design, data analysis, manuscript writing
ZYW – $PM_{2.5}$ modeling, data generation, geo-coding, data analysis
MK – PM 2.5 modeling, data generation, manuscript review and editing
DAL – data acquisition, interpretation, manuscript review and editing
SPB – data collection, manuscript review and editing
CPH – data collection, manuscript review and editing
DLD – data collection, manuscript review and editing
DB – data analysis, manuscript review and editing
EAR – conception, study design,

Support: This work was supported by NHLBI grants U01 HL089897 and U01 HL089856 and by NIH contract 75N92023D00011. The COPDGene study (NCT00608764) has also been supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion

Abstract

Rationale: Short term exposure to fine particulates ($PM_{2.5}$) increases the risk of respiratory exacerbations, but the effects frequently resolve. The contribution of chronic, long-term exposure, to respiratory exacerbations is poorly defined.

Objectives: To assess the long-term effects of $PM_{2.5}$ on the risk of severe exacerbations in current and former smokers.

Methods: A longitudinal cohort of current and former smokers with and without COPD study were surveyed every six months for exacerbation events. $PM_{2.5}$ concentrations at participant geo-coded addresses were estimated using satellite, reanalysis, and ground-based monitoring sources.

Measurements and Main Results:

The relative risk of severe exacerbation increased by a factor of 1.509 (CI: 1.209, 1.884; p = 0.00028) for every 10 $\mu g/m^3$ increase in long-term $PM_{2.5}$ exposure across all participants. The effect in the GOLD 0 participants was greater with a relative risk of 2.674 (1.836 -3.894, $p<0.0001$). Significant effect modifiers with greater impact of $PM_{2.5}$ included prior exacerbations, female sex, neighborhood characteristics and study period as well as smoking status, white race, disease severity, asthma diagnosis, and age at enrollment. Significant positive associations for exacerbations were identified at levels below 8 $\mu g/m^3$. Weak evidence was found for the mediation of the association between $PM_{2.5}$ exposure and present exacerbations by a history of pre-enrollment exacerbations.

Conclusions: Persistent exposure to particulate air pollution is a significant risk factor for respiratory exacerbations in current and former smokers, and in patients with or at risk of

COPD. The current primary annual EPA standard of 9μg/m^3 for $PM_{2.5}$ may be inadequate to prevent ongoing lung injury.

Key words (3-5): COPD, air pollution, exacerbations, long-term exposure, $PM_{2.5}$

Background

Heavy cigarette smoking is a well-known risk factor for Chronic Obstructive Pulmonary Disease (COPD) and other associated chronic diseases that affect millions of people around the world[1], This exposure and its consequent disease risks are associated with huge healthcare costs and extensive burden of disease [2]. However, other inhaled exposures are also commonly associated with respiratory illness and COPD including, biomass exposure, occupational exposures, and air pollution. Both current and former smokers, as well as never smokers, experience long term health impacts from air pollution[3]. Ozone, NO_2, and small particulates ($PM_{2.5}$), have adverse effects on health including increased mortality [4,5], cardiovascular disease[6], progression of emphysema and reduced lung function[7], [8,9]. Air pollution, in particular its gaseous components, have been linked to risk of COPD incidence, prevalence and progression [1,10,11]. More recent work has defined the importance of small particulates (PM2.5) in reduced lung function and COPD [11]. An important factor for understanding COPD disease progression and associated healthcare costs are the episodes of respiratory exacerbations that require hospitalization, emergency room visits, and antibiotic and/or steroid treatment. Respiratory exacerbations also impact never-smokers and smokers without COPD, particularly with short term changes in air quality[12,13]. Many studies have shown impacts of combined pollutants – ozone, particulates and NO_2.However, the role of $PM_{2.5}$ particles in acute respiratory exacerbations is less well defined, especially in smokers with a diagnosis of COPD. Further, long- vs short-term exposures to particulates appear to have different risks, with evidence of recovery following short-term exposures [14].

Air pollution intensity and constituents vary by location; an individual's residential location along with severity of local air pollution are important social determinants of health related to COPD[15,16]. Determining the sources and impact of various factors on disease risks is critical to improve outcomes of care. Smoking cessation, for example, is strongly recommended for improved health, but persistent exposure to outdoor air pollution may remain as a precipitating factor for exacerbations of disease in both current and former smokers. Other, potentially modifiable factors that affect the risk of exacerbations associated with air pollution are important to define and require detailed individual information as well as the timing and duration of exposures and the impact of specific pollution components. We studied the impact of chronic, ambient $PM_{2.5}$ concentrations on respiratory exacerbations in a well-characterized established longitudinal cohort of current and former smokers with and without COPD -the COPDGene study, over a period of 16 years (2006-2021). We hypothesized that increased long-term exposure to small particulates would be associated with increased risk of exacerbations.

Methods:

Population:

The COPDGene study enrolled 10,652 individuals at 21 clinical centers around the US who had at least a 10-pack-year history of smoking and the details have been published[17]. The COPDGene research protocol was approved by the institutional review board at each of the 21 clinical centers, and all participants provided written informed consent. Current residential address was collected from a limited number of the 10,305 participants enrolled in Phase 1 of

the study (2007-2012) and the majority of participants in Phase 2. (2012-2017). A small group of never smokers (n=454) were enrolled in Phase 1 and Phase 2 as a control group, and current address was collected from all remaining participants. Thus, a patient's enrollment may have occurred either in Phase 1 or Phase 2. In Phase 3 (2017-2023), updated address information was collected from the remaining participants.

Exacerbations

Participants in COPDGene were surveyed approximately every six months by phone or email, and asked about respiratory exacerbations that resulted in an emergency room visit or hospitalization and was accompanied by treatment with antibiotics and/or glucocorticoids and occurred "since we last spoke". Survey collection started after Phase 1 was initiated, with the first surveys administered in May 2009. A total of 103,017 of these longitudinal follow-ups (LFU) phone surveys were collected from 9,479 participants during our study period ending in December 2021. A total of 6,510 participants had at least one geocoded address and at least one phone survey; this subset of participants had 86,692 unique surveys. Of the 10,652 participants in the COPDGene cohort, a total of 1,573 addresses were obtained in Phase 1, 6,298 addresses in Phase 2, and 4,455 addresses in Phase 3, encompassing 6,719 unique individuals, and geocoded using ArcGIS Pro 2.8.0[18].

Particulate Matter

Daily $PM_{2.5}$ concentrations were previously estimated at a 1km spatial resolution raster over the contiguous U.S. for the years 2005-2021 using a geospatial artificial intelligence (GeoAI) model [19]. These daily concentrations were estimated back approximately eighteen months prior to the beginning of Phase 1 to allow calculation of long-term exposures. The GeoAI model

incorporated $PM_{2.5}$ monitor observation, satellite aerosol optical depth (imputed where missing), global reanalysis products, weather data, and elevation. A full 16-year time-series of daily $PM_{2.5}$ concentrations was assigned to each participant's geocoded residences using the raster cell into which the residences fell. These concentrations were then averaged over the time intervals between each consecutive pair of surveys. However, following a protocol change on January 1, 2014, whenever a study visit occurred between surveys the average was computed over the interval from the date of the study visit to the date of the survey rather than the interval between the surveys.

Details of how these issues were handled are provided in the supplemental methods. A total of 5,671 participants with 41,989 surveys had at least one assignable $PM_{2.5}$ exposure and were used in the analyses below. Because all time intervals were at least 59 days long, the average $PM_{2.5}$ concentrations are all considered 'long-term exposures' as defined by the U.S. Environmental Protection Agency[20]

Neighborhood Characteristics

Geocoded locations were used to identify US census tracts in which participants lived and thereby derive their tracts' 2018 area deprivation index (ADI)[21], 2018 social vulnerability index (SVI)[22], and neighborhood's Homeowners Loan Corporation (HOLC) grade from the 1930s (i.e., redlining grade)[23].

Statistical Analyses

Following geocoding, all subsequent analyses were performed in R version 4.4.2[24].

Primary Analysis

Associations between the ambient long-term average $PM_{2.5}$ concentrations and self-reported exacerbation counts during the between-survey intervals were estimated using quasi-Poisson models implemented in the gnm[25] package, with a separate fixed stratum intercept for each subject and an offset term accounting for the logarithm of the between-survey interval length. The fixed intercept accounts for all individual-level factors at enrollment including prior medical history (e.g., emphysema diagnosis, prior exacerbations) as well as time-invariant factors (e.g., race).

A crude model included only strata intercepts and $PM_{2.5}$ as predictors. Our primary model included these plus potential confounders. Because COPD can be characterized by low blood oxygen levels, the primary model controlled for residence elevation. Likewise, since COPD tends to be a progressive disease, the primary model also included nonlinear control for time using linear and quadratic time terms. Model results with $p<0.05$ were considered 'statistically significant'.

Effect Modification Analyses

To determine whether associations identified in our main model might be impacted by meteorology, time period, neighborhood and demographic factors, and medical history at baseline, we explored the modification of the $PM_{2.5}$ effect. Details are provided in the Supplementary methods.

Furthermore, since the U.S. EPA annual standard for $PM_{2.5}$ is currently 9.0 $\mu g/m^3$ while the World Health Organization's guideline is 5.0 $\mu g/m^3$, the analysis was repeated using only surveys associated with addresses where the 16-year average $PM_{2.5}$ concentration was below 9.0, 8.5, 8.0, 7.5, and 7.0 $\mu g/m^3$.

Mediation Analysis

Because prior exacerbation history is a strong predictor of future exacerbation risk, we calculated how much of the association between previous exacerbations at enrollment and between-survey exacerbations during the study was mediated by $PM_{2.5}$ exposure using the mediation package[26]. Because the main model's fixed intercepts are completely confounded with prior exacerbation history, we used random intercept models to evaluate mediation.

Results

Participants

Demographic characteristics of the cohort at enrollment are given in **Table 1**. The study included 5,671 participants, of whom 2,760 were male and 2,883 female (28 did not report their gender). The racial distribution included 4,127 whites and 1,516 Black/African-Americans (28 did not report their race). The mean age was 60 years. Most participants had some college education or were college graduates.

Health characteristics at enrollment are shown in **Table 2**. On average, participants had a BMI of 29.0, an FEV_1/height of 0.014 L/cm, an FEV_1 and FVC of 2.37 and 3.39 liters, respectively, an FEV1/FVC of 0.69, a 6-minute walk distance of 1,453 feet, a SGRQ total score of 22, a % emphysema of 5, and a MMRC dyspnea score of 1.05.

Smoking characteristics at enrollment are given in **Table 3**. Most participants were former smokers and had never experienced a severe exacerbation. In addition, most were classified as BODE 0 and nearly half were classified as GOLD 0.

Table 4 shows the distribution of participants' morbidities at enrollment, including COPD, asthma, emphysema, coronary artery disease, and congestive heart failure. In general, morbidities were relatively uncommon.

As shown in **Table 5**, the average number of reported between-survey exacerbations was 0.21, while the average between-survey interval duration was 230 days. Exacerbation rates were heavily skewed, with median of 0/year, a mean of 0.413/year, and a maximum of 73/year (Supplemental Figure S2), though the most extreme are removed in a sensitivity analysis. Fully 3,632 (64.0%) participants had no exacerbations. The time intervals between surveys were likewise skewed, with a median of 0.561 years (205 days), a mean of 0.630 years (230 days), and a maximum of 6.55 years (2394 days) (Supplemental Figure S2).

The average $PM_{2.5}$ concentration between surveys was 8.81 $\mu g/m^3$, and the average 16-year $PM_{2.5}$ was 9.73 $\mu g/m^3$. Average ADI and SVI were both 0.43 on a scale of 0-1. While most geocoded address did not fall in a neighborhood with a redlining grade, of those that did, most were in the lowest two grades (C and D).

<u>Primary Analysis</u>

The crude model estimated a factor of 1.618 (95% CI: 1.338, 1.957; $p < 0.0001$) increase in exacerbation risk per 10$\mu g/m^3$ increase in between-survey average $PM_{2.5}$ concentration. However, the main model estimated a factor of 1.509 (CI: 1.209, 1.884; $p = 0.00028$) increase for the same change in concentration.

Effect Modification Analyses

Supplemental Table S2 presents effect modification results. Among continuous modifiers, models with interactions by 16-year average $PM_{2.5}$ (p = 0.0002), SVI (p = 0.0232), ADI (p = 0.0043), and age at enrollment (p = 0.0012) had a significant improvement in model fit based on the likelihood ratio test. Among those, age and ADI had statistically significant interaction coefficients, with the $PM_{2.5}$ association strengthening with age (Supplemental Figure 7) and weakening with higher ADI (Supplemental Figure 6). The models with SVI and 16-year average $PM_{2.5}$ interactions did not yield statistically significant interaction coefficients, implying that their improvement in fit was driven by inclusion of the linear terms.

For each continuous modifier, plots of the main $PM_{2.5}$ association over the range of that modifier are given in **Supplemental Figures S2-S11**. These figures show that the association between $PM_{2.5}$ and exacerbations was positive and significant when 16-year average $PM_{2.5}$ fell in the range 2.5–12.5 $\mu g/m^3$ (S2), 16-year average daily minimum temperature in the range 2–18 °C (S3), residence elevations below 1000 meters (S4), SVI below 0.75 (S5), ADI below 0.55 (S6), age at enrollment above 55 years (S7), FEV_1/height above 0.08 L/cm (S8), % emphysema below 28% (S9), pack years below 75 (S10), and BMI between 20 and 45.

Among categorical modifiers (Supplemental Table S2), an improvement in model fit was identified for race, gender, COVID lockdown period, trichotomous year, emphysema diagnosis, asthma diagnosis, GOLD stage, BODE score, prior exacerbations, and HOLC grade. Among these, statistically significant differences were observed between Blacks and whites (p < 0.0001, higher

for Whites), males and females (p = 0.0101, higher for females), 2014 or earlier vs. 2015-2018 (p = 0.0172, higher for 2015-2018), BODE 2 and BODE >2 vs. BODE 0 (p = 0.0002 and p = 0.0290, respectively, higher for BODE 0), some vs. no prior exacerbations (p = 0.0096, higher for prior exacerbators), and HOLC grade A vs. D (p = 0.0058, higher for grade D).

In the model treating GOLD 0 as a single category we found statistically significant differences between PRISm and GOLD 2 vs. GOLD 0 (p = 0.0017 and p < 0.0001, respectively, higher for GOLD 0). Likewise, in the two-category model we found PRISm and GOLD 2 vs. GOLD 0 former smokers (p = 0.0014 and p < 0.0001, respectively, higher for GOLD 0 former smokers). In stratified results, GOLD 0 yielded the strongest association with $PM_{2.5}$ (RR = 2.67; 95% CI: 1.836, 3.984; p<0.0001) among all GOLD stages, and, when split into two categories, GOLD 0 former smokers had a stronger association (RR = 3.075; 95% CI: 1.873, 5.049; p < 0.0001) than GOLD 0 current smokers (RR = 2.242; 95% CI: 1.284, 3.916; p = 0.0045).

These results indicate that the exacerbation risk associated with $PM_{2.5}$ was higher for participants who were white and female, those with prior exacerbations and less smoking history and disease progression at enrollment, those who were older but weighed less at enrollment, and those living in neighborhoods with less deprivation now but more historical disinvestment.

<u>Sensitivity Analyses</u>

Supplemental Table S3 presents sensitivity results. Associations remained positive under all sensitivity analyses except the model with linear control for time, with risk ratios ranging from 1.310 to 1.766 per 10μg/m^3 increase in $PM_{2.5}$. The binomial model analyzing presence or absence of exacerbations yielded an odds ratio of 2.229 (95% CI: 1.634, 3.040; $p < 0.0001$) while the random intercept model yielded a risk ratio of 1.454 (95% CI: 1.170, 1.830; $p = 0.0008$) for the same exposure change. Using only surveys with short interval periods had no qualitative impact on the result (Supplemental Figure S4). Using only surveys taken while subjects lived at residences with 16-year average $PM_{2.5}$ below the current standard yielded a statistically significant positive association below 9 μg/m^3, 8.5 μg/m^3, and 8 μg/m^3. Using only surveys with an implied exacerbation rate of <20/year yielded a risk ratio of 1.517 (95% CI: 1.227, 1.876, $p = 0.0001$).

Mediation Analysis

Prior exacerbations at enrollment increased the risk of exacerbation during the study by a factor of 6.128 (95% CI: 5.037, 7.466; $p < 0.0001$), but only 0.27% (95% CI: -0.02, 0.72; $p = 0.0650$) of this association was mediated by $PM_{2.5}$ exposure.

Discussion

We estimated a positive association between $PM_{2.5}$ exposure and exacerbation risk, corresponding to a 50.9% increase in risk for each 10 μg/m^3 increase in $PM_{2.5}$. In addition, we found that the exacerbation risk driven by $PM_{2.5}$ exposure tended to be higher among populations considered less sensitive or vulnerable in some ways (whites, patients living in less

deprived areas, and patients with little disease progression) and more sensitive or vulnerable in other ways (females, older patients, patients with prior exacerbation history, patients living in historically disinvested areas, patients with moderate disease progression). Participants without spirometric obstruction (GOLD 0) at enrollment had the strongest $PM_{2.5}$ association among all subgroups, and, within that group, the former smokers had a stronger association than current smokers. No subgroup of participants had a protective association with $PM_{2.5}$ except the small number (N = 85) living in HOLC grade A neighborhoods. We found little evidence that $PM_{2.5}$ mediates the impact of prior exacerbation history on future exacerbations.

Our mixed results in terms of vulnerability or susceptibility factors belie the complexity of real-world multi-domain exposures through the lifecourse and their potentially countervailing impacts on COPD patients' sensitivity to air pollution.

This work is the first to study the impact of $PM_{2.5}$ on respiratory outcomes in a well-characterized COPD cohort of this size and opens the door to future studies investigating $PM_{2.5}$ associations with lung imaging measures and molecular endpoints, as well as multi-pollutant impacts.

This work has several limitations. First, because addresses were collected on different days than the phone surveys, we necessarily made an assumption regarding when participants moved between residences in order to assign exposures to between-survey intervals. We explored a different assumption in a sensitivity analysis, but other assumptions are possible. Second,

exposures were estimated not measured, so errors in our $PM_{2.5}$ estimates may affect our results; however, the error involved is of the Classical type, which usually yields associations that are less strong than the true association. Furthermore, modeling work on other outcomes has shown that using $PM_{2.5}$ estimated with error yields results similar to the truth[27].

Beyond potential clinical importance, our results have regulatory implications. A significant positive association was observed in areas with 16-year average $PM_{2.5}$ concentrations below 8.0 $\mu g/m^3$, which is below the current U.S. EPA $PM_{2.5}$ level annual standard. This indicates that, at least in the population studied here, the standard may not be sufficiently protective. Moreover, regulation of $PM_{2.5}$ is largely justified based on its relationships with mortality and cardiovascular health effects, not respiratory health effects, so demonstrating a respiratory health effect due to long-term $PM_{2.5}$ exposure further increases the evidence basis for standard setting.

Characteristic	N = 5,671[1]
Gender	
Male	2,760 (49%)
Female	2,883 (51%)
Missing	28 (0.5%)
Race	
White	4,127 (73%)
Black/African-American	1,516 (27%)
Missing	28 (0.5%)
Income	
Under $15,000	940 (17%)
$15,000 - $35,000	1,109 (20%)
$35,000 - $50,000	708 (12%)
$50,000 - $75,000	732 (13%)
More than $75,000	771 (14%)
Decline to Answer	1,411 (25%)
Education Level	
8th Grade or Less	87 (1.5%)
High School, No Diploma	453 (8.0%)
High School Graduate or GED	1,240 (22%)
Some College or Technical School	1,540 (27%)
College or Technical School Graduate	1,616 (28%)
Master's or Doctoral Degree	707 (12%)
Missing	28 (0.5%)
Age (years)	60 (9)
Missing	28

[1] n (%); Mean (SD)

Table 1: Air Pollution Analysis Participantdemographics at enrollment visit

Characteristic	N = 5,671[1]
Body Mass Index	29.0 (6.0)
Missing	28
FEV1/Height (L/cm)	0.014 (0.005)
Missing	50
FEV1 (L)	2.37 (0.86)
Missing	50
FVC (L)	3.39 (0.97)
Missing	50
FEV1/FVC	0.69 (0.14)
Missing	50
6 Minute Walk Distance (ft)	1,453 (376)
Missing	66
MMRC Dyspnea Score	
0	3,013 (53%)
1	799 (14%)
2	669 (12%)
3	811 (14%)
4	342 (6.1%)
Missing	37
SGRQ Total Score	22 (21)
Missing	28
% Emphysema (Thirona)	5 (8)
Missing	319

[1] Mean (SD); n (%)

Table 2: Participants' health status at enrollment visit

Characteristic	N = 5,671[1]
Smoking Status	
Current	2,420 (43%)
Not Current	3,223 (57%)
Missing	28 (0.5%)
Severe Exacerbations	
No	5,179 (91%)
Yes	464 (8.2%)
Missing	28 (0.5%)
Pack Years (ATS)	37 (23, 51)
Missing	31
GOLD Stage	
GOLD 0	2,466 (43%)
PRISm	642 (11%)
GOLD 1	468 (8.3%)
GOLD 2	1,031 (18%)
GOLD 3	519 (9.2%)
GOLD 4	135 (2.4%)
Never Smokers	360 (6.3%)
Missing	50 (0.9%)
BODE	
0	2,943 (52%)
1	832 (15%)
2	636 (11%)
>2	1,163 (21%)
Missing	97 (1.7%)

[1] n (%); Median (Q1, Q3)

Table 3: Participants' smoking characteristics at enrollment visit

Characteristic	N = 5,671[1]
COPD	
No	3,502 (62%)
Yes	1,463 (26%)
Don't Know/Missing	706 (12%)
Asthma	
No	4,341 (77%)
Yes	933 (16%)
Don't Know/Missing	397 (7.0%)
Emphysema	
No	4,260 (75%)
Yes	1,006 (18%)
Don't Know/Missing	405 (7.1%)
Coronary Artery Disease	
No	5,297 (93%)
Yes	346 (6.1%)
Missing	28 (0.5%)
Congestive Heart Failure	
No	5,524 (97%)
Yes	119 (2.1%)
Missing	28 (0.5%)

[1] n (%)

Table 4: Participants' comorbidities at enrollment visit

Characteristic	N = 41,989[1]
Between Survey Exacerbations	0.21 (0.73)
Between Survey Duration (days)	230 (131)
Between Survey PM2.5 (µg/m3)	8.81 (1.74)
16-Year Average PM2.5 (µg/m3)	9.73 (1.54)
Area Deprivation Index (ADI)	0.43 (0.25)
Missing	210
Social Vulnerability Index (SVI)	0.43 (0.28)
Missing	39
Elevation (km)	0.37 (0.53)
Redlining Grade	
D	3,228 (7.7%)
C	4,337 (10%)
B	2,577 (6.1%)
A	496 (1.2%)
None	31,351 (75%)

[1] Mean (SD); n (%)

Table 5: Participants' environmental and social exposures based on address proximal to phone surveys

Characteristic	None N = 3,632[1]	0-1 per year N = 1,348[1]	>1 per year N = 691[1]
Average PM2.5 (µg/m3)	8.85 (1.53)	8.80 (1.39)	8.95 (1.65)
Age (years)	60 (9)	61 (8)	59 (9)
Missing	11	10	7
Gender			
Male	1,895 (52%)	558 (41%)	307 (44%)
Female	1,726 (48%)	780 (58%)	377 (55%)
Missing	11 (0.3%)	10 (0.7%)	7 (1.0%)
Race			
White	2,615 (72%)	1,043 (77%)	469 (68%)
Black/African-American	1,006 (28%)	295 (22%)	215 (31%)
Missing	11 (0.3%)	10 (0.7%)	7 (1.0%)
Smoking Status			
Current	1,553 (43%)	549 (41%)	318 (46%)
Former	2,068 (57%)	789 (59%)	366 (53%)
Missing	11 (0.3%)	10 (0.7%)	7 (1.0%)
COPD			
No	2,557 (70%)	722 (54%)	223 (32%)
Yes	566 (16%)	489 (36%)	408 (59%)
Don't Know/Missing	509 (14%)	137 (10%)	60 (8.7%)
Emphysema			
No	3,032 (83%)	898 (67%)	330 (48%)
Yes	391 (11%)	341 (25%)	274 (40%)
Don't Know/Missing	209 (5.8%)	109 (8.1%)	87 (13%)
Area Deprivation Index (ADI)	2.91 (2.65)	4.04 (3.07)	3.02 (2.78)
Missing	26	5	6
Social Vulnerability Index (SVI)	2.89 (2.57)	4.00 (3.12)	3.30 (2.82)
Missing	1	2	2

[1] Mean (SD); n (%)

Table 6: Exposure and demographic information by participant exacerbation rate

References

1. Sin DD, Doiron D, Agusti A, et al. Air pollution and COPD: GOLD 2023 committee report. *European Respiratory Journal*. 2023-05-11 2023;61
2. Boers E, Barrett M, Su JG, et al. Global Burden of Chronic Obstructive Pulmonary Disease Through 2050. *JAMA Netw Open*. Dec 1 2023;6(12):e2346598. doi:10.1001/jamanetworkopen.2023.46598
3. Manisalidis I, Stavropoulou E, Stavropoulos A, Bezirtzoglou E. Environmental and Health Impacts of Air Pollution: A Review. *Front Public Health*. 2020;8:14. doi:10.3389/fpubh.2020.00014
4. Hao Y, Balluz L, Strosnider H, Wen XJ, Li C, Qualters JR. Ozone, Fine Particulate Matter, and Chronic Lower Respiratory Disease Mortality in the United States. *Am J Respir Crit Care Med*. Aug 1 2015;192(3):337-41. doi:10.1164/rccm.201410-1852OC
5. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL. Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. *The New England journal of medicine*. Dec 14 2000;343(24):1742-9. doi:10.1056/NEJM200012143432401
6. Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the triggering of myocardial infarction. *Circulation*. Jun 12 2001;103(23):2810-5. doi:10.1161/01.cir.103.23.2810
7. Wang M, Aaron CP, Madrigano J, et al. Association Between Long-term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function. *JAMA : the journal of the American Medical Association*. Aug 13 2019;322(6):546-556. doi:10.1001/jama.2019.10255
8. Thi Khanh HN, De Troeyer K, Smith P, Demoury C, Casas L. The impact of ambient temperature and air pollution on SARS-CoV2 infection and Post COVID-19 condition in Belgium (2021-2022). *Environ Res*. Dec 29 2023;246:118066. doi:10.1016/j.envres.2023.118066
9. Kalluci E, Noka E, Bani K, et al. Correlation between COVID-19 and air pollution: the effects of PM2.5 and PM10 on COVID-19 outcomes. *Eur Rev Med Pharmacol Sci*. Dec 2023;27(6 Suppl):39-47. doi:10.26355/eurrev_202312_34688
10. Park J, Kim HJ, Lee CH, Lee CH, Lee HW. Impact of long-term exposure to ambient air pollution on the incidence of chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Environ Res*. Mar 2021;194:110703. doi:10.1016/j.envres.2020.110703
11. Doiron D, de Hoogh K, Probst-Hensch N, et al. Air pollution, lung function and COPD: results from the population-based UK Biobank study. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology*. Jul 2019;54(1)doi:10.1183/13993003.02140-2018
12. Ross BA, Doiron D, Benedetti A, et al. Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort. *Thorax*. Oct 2023;78(10):974-982. doi:10.1136/thorax-2022-219619
13. Doiron D, de Hoogh K, Probst-Hensch N, et al. Residential Air Pollution and Associations with Wheeze and Shortness of Breath in Adults: A Combined Analysis of Cross-Sectional Data

from Two Large European Cohorts. *Environmental health perspectives*. Sep 29 2017;125(9):097025. doi:10.1289/EHP1353
14. Guo C, Zhang Z, Lau AKH, et al. Effect of long-term exposure to fine particulate matter on lung function decline and risk of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. *Lancet Planet Health*. Mar 2018;2(3):e114-e125. doi:10.1016/S2542-5196(18)30028-7
15. Jbaily A, Zhou X, Liu J, et al. Air pollution exposure disparities across US population and income groups. *Nature*. Jan 2022;601(7892):228-233. doi:10.1038/s41586-021-04190-y
16. Levy JI, Quiros-Alcala L, Fabian MP, Basra K, Hansel NN. Established and Emerging Environmental Contributors to Disparities in Asthma and Chronic Obstructive Pulmonary Disease. *Curr Epidemiol Rep*. Jun 2018;5(2):114-124. doi:10.1007/s40471-018-0149-9
17. Regan EA, Hokanson JE, Murphy JR, et al. Genetic epidemiology of COPD (COPDGene) study design. *Copd*. Feb 2010;7(1):32-43. doi:10.3109/15412550903499522
18. *ArcGIS Pro*. Version 2.8.0. Esri (Environmental Systems Research Institute);
19. Wang Z, Crooks JL, Regan EA, Karimzadeh M. High-Resolution Estimation of Daily PM2.5 Levels in the Contiguous US Using Bi-LSTM with Attention. *Remote Sensing*. 2025;17(1). doi:10.3390/rs17010126
20. Agency" EP. Regulatory Impact Analysis for the Proposed Reconsideration of the National Ambient Air Quality Standards for Particulate Matter. In: Agency EP, editor.: National Service Center for Environmental Publications (NSCEP); 2022. p. 467.
21. Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. *The New England journal of medicine*. Jun 28 2018;378(26):2456-2458. doi:10.1056/NEJMp1802313
22. CDC/ATSDR Social Vulnerability Index 2019 Database (2020).
23. Nelson RK, Winling L. Mapping Inequality: Redlining in New Deal America. Accessed 10/05/2023. https://dsl.richmond.edu/panorama/redlining
24. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Accessed 13 Aug 2018, https://www.R-project.org/
25. Turner H, Firth D. *Generalized nonlinear models in R: An overview of the gnm package*. 2020. https://cran.r-project.org/package=gnm
26. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. *Journal of Statistical Software*. 09/02 2014;59(5):1 - 38. doi:10.18637/jss.v059.i05
27. Wei Y, Qiu X, Yazdi Mahdieh D, et al. The Impact of Exposure Measurement Error on the Estimated Concentration–Response Relationship between Long-Term Exposure to PM2.5 and Mortality. *Environmental health perspectives*. 130(7):077006. doi:10.1289/EHP10389